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Abstract 
Antibodies have been widely used to provide targeting ability and to enhance bioactivity owing to their high specific‑
ity, availability, and diversity. Recent advances in biotechnology and nanotechnology permit site‑specific engineering 
of antibodies and their conjugation to the surfaces of nanoparticles (NPs) in various orientations through chemical 
conjugations and physical adhesions. This study proposes the conjugation of poly(lactic‑co‑glycolic acid) (PLGA) NPs 
with antibodies by using two distinct methods, followed by a comparison between the cell‑targeting efficiencies of 
both techniques. Full‑length antibodies were conjugated to the PLGA‑poly(ethylene glycol)‑carboxylic acid (PLGA‑
PEG‑COOH) NPs through the conventional carbodiimide coupling reaction, and f(ab′)2 antibody fragments were con‑
jugated to the PLGA‑poly(ethylene glycol)‑maleimide(PLGA‑PEG‑Mal) NPs through interactions between the f(ab′)2 
fragment thiol groups and the maleimide located on the nanoparticle surface. The results demonstrate that the PLGA 
nanoparticles conjugated with the f(ab′)2 antibody fragments had a higher targeting efficiency in vitro and in vivo 
than that of the PLGA nanoparticles conjugated with the full‑length antibodies. The results of this study can be built 
upon to design a delivery technique for drugs through biocompatible nanoparticles.
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1 Introduction
 Antibodies have been widely used as active pharmaceu-
tical ingredients, targeting ligands, and biosensing mol-
ecules in pharmaceutical and biomedical fields [1–3]. 
The rapid advancements in antibody development and 
large-scale production technologies have promoted the 
applications of antibodies in several fields [4, 5]. Antibod-
ies are often chemically conjugated or physically adhered 
to the surfaces of biomaterial-based nanoparticles (NPs) 
and sensing platforms to ensure specific targeting or/and 
enhanced bioactivity due to their high specificity, remark-
able diversity, and high availability. Such bioconjugates 
have already been successful in several biomedical fields, 
including biosensors [6–14] and targeted drug delivery 
[15–19]. Previous studies have demonstrated that NPs 
coated with antibodies have significantly enhanced drug 
delivery profiles in comparison to those of conventional 
drug carriers [20, 21]. In addition, modern breakthroughs 
in biotechnology and nanotechnology have enabled reli-
able site-specific engineering of antibodies and their con-
jugations on the surfaces of NPs in various orientations 
through distinct techniques.
The carbodiimide coupling reaction is a conventional 
technique that is widely used to conjugate antibodies 
to the surfaces of NPs [22–24]. This method involves 
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activation of the carboxyl groups on the surface of the 
NPs, which can then be covalently conjugated to the 
amine groups of the antibodies. This technique is incred-
ibly convenient for polymers functionalized with reactive 
carboxyl groups in their side chains [25–27]. However, 
several studies have reported that this reaction results in 
undesirable agglomeration and uncontrolled orientation 
of the conjugated antibodies, which reduces the conjuga-
tion efficiency of the antibodies [16, 19, 28, 29].
Another commonly used technique involves the con-
jugation of antibody fragments to the surfaces of NP 
surfaces instead of full-length antibodies. The antibody 
fragments were conjugated to the surfaces of the NPs by 
utilizing a chemical reaction between the maleimide and 
the thiol groups of the f(ab′)2 fragments [30]. Although 
the production of the f(ab′)2 fragments is expensive and 
conducted limitedly on certain IgG types [31, 32], the 
f(ab′)2 fragments generally exhibit higher specificity and 
stability in  vivo due to the absence of various  Fc–medi-
ated effector functions (e.g., antibody-dependent cellu-
lar cytotoxicity and phagocytosis) [33]. These superior 
characteristics of the f(ab′)2 fragments should provide 
enhanced in vivo profiles and target-binding abilities 
even when they are conjugated to the NPs. However, a 
direct head-to-head comparison between the targeting 
efficiency of NPs conjugated with full-length antibodies, 
and that of NPs conjugated with f(ab′)2 fragments has not 
been conducted.
Therefore, this study compares the cell-targeting effi-
ciencies of the PLGA NPs conjugated with the f(ab′)2 
fragments and full-length antibodies. The PLGA NPs 
were prepared by using conventional emulsification 
methods [34–36]. Full-length antibodies and f(ab′)2 
fragments were chemically conjugated to their surfaces 
through conventional carbodiimide chemistry. The 
CD8a antibody was used as a model antibody in this 
study. CD8a is a cell surface glycoprotein and a marker 
of cytotoxic T lymphocytes [37]. It is easy to evaluate the 
cell-targeting abilities of CD8 T cells in vitro and in vivo 
because they are abundantly present in mouse models 
[38]. Full-length CD8a antibodies were conjugated to the 
PLGA NPs by using the carbodiimide coupling method 
to prepare Full-CD8a NPs. However, the f(ab′)2-CD8a 
NPs were prepared by conjugating the f(ab′)2 fragments 
to the PLGA NPs through maleimide reaction chemistry 
[30]. These antibody-conjugated NPs were first charac-
terized to confirm the morphology, size, and complete 
conjugation of the antibodies. The number of antibod-
ies conjugated to the surfaces of the NPs was quantified 
by using the BCA assay, followed by an evaluation of 
the antibody’s biding stability. The anti-CD8a antibodies 
were conjugated to fluorescent PLGA NPs by using dif-
ferent conjugation methods to observe their targeting 
efficiency towards CD8 T cells. After treating the two 
types of NPs, the immune cells targeted with the CD8a 
NPs were analyzed through flow cytometry in vitro and 
in vivo.
2  Methods/experimental
2.1  Preparation and characterizations of the conjugated 
NPs
PLGA NPs were prepared by using conventional emul-
sification methods [34–36]. The f(ab′)2-CD8a NPs were 
prepared by dissolving 22.5  mg of PLGA  (Mw: 10 000–
15 000 Da, LG 50:50, PolySciTech, NH, USA) and 7.5 mg 
PLGA-poly(ethylene glycol)-maleimide (PLGA-PEG-
Mal,  Mw: 10 000:5000 Da, LG 50:50, PolySciTech, NH, 
USA) in 1 mL of dichloromethane (DCM). The mixture 
was then poured into a 10 ml ice-cold solution of 2 % 
(w/v) poly(vinyl alcohol) (PVA). The resulting polymer 
solution was then sonicated for 10 min at a 20 % (140 W) 
amplitude according to the one sec-on and one sec-off 
sequence (Qsonica, CT, USA). The resulting emulsion 
was then stirred at room temperature for 4  h to com-
pletely evaporate the DCM. The PLGA-PEG-Mal NPs 
were collected through centrifugation at 17,000 rpm for 
20 min. The collected NPs pellets were then washed with 
deionized (DI) water thrice through centrifugation at 
17,000 rpm for 20 min.
Full-CD8a NPs were produced through a simi-
lar process; however, PLGA-poly(ethylene glycol)-
COOH (PLGA-PEG-COOH, Mw: 10,000:5000 Da, 
LG:50:50, Ruixibiotech, Shannxi, China) (PLGA-PEG-
COOH) was used instead of PLGA-PEG-Mal. The 
nanoparticles were traced through flow cytometry by 
adding 5 µg of DiIC18(5); 1,1′-dioctadecyl-3,3,3′,3′-
tetramethylindodicarbocyanine, 4-chlorobenzenesul-
fonate salt (DiD, λEx/λEm: 644/663, Biotium, CA, USA) 
to 1  mg of NPs. The size, morphology, and zeta poten-
tial of the NPs were analyzed by using a Malvern Zeta-
sizer Nano ZS system (Malvern Instruments, MA, USA), 
dynamic light scattering (DLS), and a JEM-7500  F 
(Akishima, Japan) scanning electron microscope (SEM).
2.2  Conjugation of the antibodies to the NPs
The f(ab′)2-CD8a NPs, f(ab′)2 antibody fragments were 
chemically conjugated to the NPs by adopting a previ-
ously reported method [30]. Protease IdeS (Promega, 
WI, USA) was used to cleave full-length CD8a antibodies 
(Clone: 2.43; BioXcell, NH, USA) to the f(ab′)2 fragments. 
The f(ab′)2 fragments were then reduced with 2.5 µL of 
10 mM DTT per 100 µg of antibodies to obtain free thiol 
groups in the hinge region. The free DTT was removed 
from the f(ab′)2 fragments by using 7  kDa MWCO 
desalting columns (Thermo Scientific, MA, USA) after 
reduction. This was followed by the addition of 5, 12.5, 
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and 25 µg of antibodies to 1 mg of PLGA-PEG-Mal NPs 
(8 mg/mL) and incubation under shaking conditions (2 h, 
25 °C). The BCA assay was used to quantify the number 
of antibodies conjugated to the surfaces of the NPs sur-
face in comparison to the net number of antibodies ini-
tially added to the mixture.
The preparation of the full-CD8a NPs involved direct 
conjugation of the CD8a antibodies to the NPs through 
a carbodiimide coupling reaction [39]. N-hydroxysulfo-
succinimide (NHS, 200 mM, 240 µL) and 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide (EDC, 200 mM, 24 
µL) were added to the PLGA-PEG-COOH NPs (5  mg/
mL, 1mL) to activate the carboxyl group of the NPs. The 
activated PLGA-PEG-COOH NPs were washed with 1 
× PBS thrice. The antibodies were added to the PLGA-
PEG-COOH NPs and coupled at a ratio of 25 or 50  µg 
of antibodies per 1 mg of NPs. The duration of the NPs 
incubated with NHS/EDC for activation or antibody 
coupling are listed in Tables 1 and 2. The BCA assay was 
used to confirm the conjugation of antibodies to NPs. A 
standard reference curve was first established by add-
ing the same amount of bare NPs to each well and then 
adding adifferent amount of antibodies to each well. The 
BCA assay data of antibody-conjugated NPs were then 
carefully analyzed upon the standard curve.
2.3  In vitro binding stability of the antibodies conjugated 
to the NPs
The binding stability of the antibodies conjugated to 
f(ab′)2-CD8a and full-CD8a NPs was evaluated by dis-
persing 4  mg/mL of the antibody-conjugated NPs in 
Dulbecco’s phosphate-buffered saline (DPBS) and incu-
bating in a shaker at 25 ℃. The solution was centrifuged 
at 17,000 rpm for 20 min after incubating the mixture for 
a fixed duration (1, 3, 5, and 7 days). The resulting super-
natant was analyzed for its antibody content by using the 
BCA assay. The stability of the antibody conjugation was 
evaluated by comparing the initial number of antibod-
ies conjugated to the NPs and the number of antibod-
ies that detached from the NPs after 1, 3, and 5 days of 
incubation.
2.4  Animals
Experiments were conducted on animals in accordance 
with the protocols approved by the Institutional Ani-
mal Care and Use Committee (IACUC) of Sungkyunk-
wan University College of Medicine (IACUC No. SKKU 
IACUC2021-01-33-3). Six- to seven-week-old C57BL/6 
male mice (18–20  g) were obtained from Orient Bio 
(Seongnam, Korea). The mice were provided an accli-
matization period of seven days before commencing the 
experiment. Five animals were housed in each cage at an 
automatically controlled temperature and humidity of 
20–26 °C and 40–60 %, respectively, with a 12:12 h light/
dark cycle. The mice were fed a standard rodent pellet 
diet and supplied with water ad libitum.
2.5  Evaluation of the immune cell‑targeting ability 
of the NPs in vitro
The in  vitro targeting efficiency of the NPs was inves-
tigated by using mouse splenocytes. The spleen of a 
C57BL/6 mouse (6-week-old) was first extracted. It was 
triturated on a 70 μm cell strainer by using the rear end 
of the plunger of a 1 mL syringe. The gathered cells were 
then centrifuged at 1500 rpm for 5 min. The pellets were 
then re-suspended in 5 mL of ACK lysis buffer (Gibco, 
MA, USA) for 3  min to eliminate red blood cells. The 
splenocytes were collected after centrifuging the cells at 
1500 rpm for 5 min. DiD-loaded NPs were co-incubated 
with mouse splenocytes (2 ×  106 cells) in a 96 well plate 
while they were suspended in DPBS. The cells were 
treated with different concentrations of DiD-loaded NPs 
for a duration that varied from 30 to 180 min. The cells 
were washed in DPBS thrice after co-incubation. Our tar-
get immune cells were then assessed through flow cytom-
etry. The antibodies used to gate the target immune cells 
include Zombie Violet (Biolegend, CA, USA) for Live/
Dead staining, PE-TCR β chain (Clone: H57-597; Bioleg-
end, CA, USA), PE/Cy7-CD4 (Clone: GK 1.5; Biolegend, 
CA, USA), and FITC-CD8a (Clone: 53−6.7; Biolegend, 
CA, USA).
2.6  Evaluation of the immune cell‑targeting efficiency 
of the NPs in vivo
DiD was added at 10 µg per 2  mg of f(ab′)2-CD8a NPs, 
followed by injecting the NPs into the tail veins of 
C57BL/6 mice. The blood and spleen samples of the mice 
were harvested for subsequent analysis after euthanizing 
them at preset time points (1, 3, or 6 h). The CD8 T cells 
were then assessed for DiD signals through flow cytom-
etry to evaluate the NPs’ in vivo cell-targeting efficiency.
2.7  Statistical analyses
Statistical analyses were conducted by using 2-way 
ANOVA, and 1-way ANOVA with Sidak’s multiple 
comparisons test through the Graphpad Prism soft-
ware. The data obtained in this study were formatted as 
“mean ± standard error of the mean” or “mean ± stand-
ard deviation (SD)” with a significance set of P < 0.05. In 
addition, the P-values and detailed information for each 
experiment was provided in each Figures’ legends.
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3  Results and discussion
3.1  Preparation and characterization 
of the PLGA‑PEG‑COOH NPs and PLGA‑PEG‑Mal NPs
The PLGA NPs were prepared through a single emulsion 
method [34–36], and the CD8a antibodies were conju-
gated to the surfaces of the NPs through carbodiimide 
[22] and maleimide techniques [30] (Scheme  1; Addi-
tional file 1: Fig S1). The f(ab′)2-CD8a NPs were synthe-
sized by first cleaving full-length antibodies to f(ab′)2 and 
fc fragments using the protease IdeS. The presence of 
characteristic bands confirmed the successful fragmen-
tation of anti-CD8a during a non-reducing SDS-PAGE 
analysis (Additional file 1: Fig. S3). DTT was then used to 
create a free thiol group in the hinge region of the f(ab′)2 
fragments.
The morphologies and sizes of both NPs were evalu-
ated with SEM and DLS. The average sizes of the non-
conjugated-PLGA-PEG-Mal NPs and f(ab′)2-CD8a NPs 
were measured with DLS to be 193 and 201 nm, respec-
tively (Additional file 1: Fig. S2A). Similarly, the average 
sizes of the non-conjugated-PLGA-PEG-COOH NPs and 
full-CD8a NPs were 195 nm and 205 nm, respectively 
(Additional file  1: Fig. S2B). These results are consist-
ent with previous hypotheses that state that the sizes of 
the PLGA NPs are primarily determined by their poly-
mer concentrations and weights instead of their surface 
functional groups [40, 41]. Since the size of a full-length 
antibody is approximately 10 nm [29], the slight increase 
in the size of the NP observed after antibody conjuga-
tion can be attributed to the presence of the conjugated 
surface antibodies. The absence of the fc region can also 
explain why the f(ab′)2-CD8a NPs are slightly smaller 
than full-CD8a NPs. Further, SEM images of the full-
CD8a NPs and f(ab′)2-CD8a NPs confirmed that there 
were no significant variations between the spherical mor-
phologies and sizes of the NPs before and after antibody 
conjugation (Fig.  1A, B). The zeta potentials of PLGA-
PEG-Mal NPs and f(ab′)2-CD8a NPs were − 22.3 mV and 
− 6.78 mV, respectively (Fig. 1C). The zeta potentials for 
PLGA-PEG-COOH NPs and full-CD8a NPs were each 
− 22.9 mV and − 6.49 mV (Fig. 1D). In general, the sur-
face charges of all PLGA NPs were negative [42, 43]. The 
less negative zeta potential of the antibody-conjugated 
NPs can therefore be explained by the presence of anti-
bodies on the NPs’ surface.
3.2  Measurement of the number of antibodies conjugated 
to the surfaces of the NPs
The feed number of the antibodies and the reaction time 
were varied to study the antibody conjugation efficiency. 
The NPs were prepared under different conditions to 
observe the impact of different parameters on antibody 
conjugation and to different models of NPs for further 
applications.
The duration of the COOH activation in full-CD8a 
NPs, which was induced by the carbodiimide reaction, 
and the coupling duration were varied. The net amount 
of anti-CD8a (25–50 µg) added to the coupling reaction 
was also varied. It was observed that the increased activa-
tion time, coupling time, and initial number of antibodies 
increased the final number of antibodies conjugated to 
Table 1 The amounts of anti‑CD8a Ab conjugated to the PLGA‑PEG‑COOH NPs. The amounts (µg) of antibodies conjugated to 
1 mg of the PLGA‑PEG‑COOH NPs when antibodies were initially added at 25 µg per 1 mg of NPs was measured by BCA assay (n = 3, 
mean ± SD)
Coupling time (h) Activation time (h)
3 6 10
 3 1.74 ± 0.39 3.48 ± 0.44 2.90 ± 0.59 
 6 2.42 ± 0.72 3.61 ± 0.50 3.41 ± 1.00 
 10 3.36 ± 0.40 3.86 ± 0.32 5.25 ± 0.30 
Table 2 The amounts of anti‑CD8a Ab conjugated to the PLGA‑PEG‑COOH NPs. The amounts (µg) of antibodies conjugated to 
1 mg of the PLGA‑PEG‑COOH NPs when antibodies were initially added at 50 µg per 1 mg of NPs was measured by BCA assay (n = 3, 
mean ± SD)
Coupling time (h) Activation time (h)
3 6 10
 3 3.56 ± 0.58 4.82 ± 0.29 4.34 ± 0.66 
 6 5.28 ± 0.49 4.82 ± 0.50 6.31 ± 0.35 
 10 5.28 ± 0.75 5.55 ± 0.27 7.32 ± 0.95 
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the NPs (Tables 1, 2). It was also observed that an incre-
ment in initial concentration of the f(ab′)2 fragments 
during their reaction with the PLGA-PEG-Mal NPs sig-
nificantly increased the number of antibodies conjugated 
to the surfaces of the NPs (Table 3).
Three types of f(ab′)2-CD8a NPs, namely f(ab′)2-
CD8a NPs-low, f(ab′2-CD8a NPs-medium, and f(ab′)2-
CD8a NPs-high with 1.32 ± 0.36, 5.19 ± 0.16, and 
11.80 ± 0.01  µg/mg of coated antibody fragments, were 
selected for additional in vitro and in vivo experiments. 
We also selected three full-CD8a NPs with correspond-
ing numbers of conjugated antibodies (i.e., the numbers 
of coated full-length antibodies for the full-CD8a NPs-
low, full-CD8a NPs-medium, and full-CD8a NPs-high 
variants were 1.74 ± 0.39, 5.28 ± 0.49, and 7.32 ± 0.95 µg/
mg, respectively).
Scheme 1 Schematic of the synthetic route of the antibody‑conjugated NPs. (Upper) Synthesis of the full‑CD8a NPs. The EDC activates the COOH 
group of the PLGA NPs, and the NHS subsequently forms a stabilized amine‑reactive sulfo‑NHS ester. This allows the  NH2 group of the antibody to 
bind with the amine‑reactive sulfo‑NHS ester on the NP surface. (lower) Synthesis of the f(ab′)2‑NPs. An antibody was first cleaved by using IdeS. It 
was then reduced by DTT to obtain a free thiol group in its hinge region. The free thiol group binds with the Mal located on the NP surface
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The efficiency of the antibody conjugation to the sur-
faces of the NPs was calculated by setting the total num-
ber of antibodies added to the particles to 100 % (Fig. 2A). 
The efficiencies of the full-CD8a NPs-low, medium, and 
high variants were 6.96 %, 10.55 %, and 14.64 %, respec-
tively. Similarly, the efficiencies of the f(ab′)2-CD8a NPs-
low, medium, and high variants were 26.44 %, 41.53 %, 
and 47.19 %, respectively. This indicates that the con-
jugation of the f(ab′)2 fragments to the surface of the 
PLGA-PEG-Mal NPs was more efficient than that of the 
full-length antibodies to the PLGA-PEG-COOH NPs.
Fig. 1 Morphological and zeta potential analysis of the PLGA NPs through scanning electron microscopy (SEM) and dynamic light scattering 
(DLS). A SEM image of non‑conjugated PLGA‑PEG‑COOH NPs and Full‑CD8a NPs. B SEM image of non‑conjugated PLGA‑PEG‑Mal NPs and 
f(ab′)2‑CD8a NPs (Scale bar = 0.5 μm). C Zeta potential of PLGA‑PEG‑Mal NPs and f(ab′)2‑CD8a NPs. D Zeta potential of PLGA‑PEG‑COOH NPs and 
Full‑CD8a NPs
Table 3 The amounts of anti‑CD8a Ab conjugated to the PLGA‑
PEG‑Mal NPs. The amounts of antibodies conjugated to 1 mg of 
PLGA‑PEG‑Mal NPs when different numbers of antibodies were 
added initially was measured by BCA assay (n = 3, mean ± SD)
Feed amount of Anti‑CD8a Ab (per 
1 mg NPs, µg)
5 12.5 25
Amounts of conjugated Anti‑
CD8a Abs
(per 1 mg NPs, µg)
1.32 ± 0.36 5.19 ± 0.16 11.80 ± 0.01
Fig. 2 Conjugation efficiency and stability of the antibodies to the 
surface of NPs. A Conjugation efficiency of each NPs compared 
with added antibody. Data were presented as the mean ± SD 
(n = 3, ****P < 0.0001). B The binding stability of the antibodies 
conjugated to the NPs is determined by the change in the number 
of antibodies bound to the NP surface over the incubation period (25 
℃, shaking condition). Data were presented as the mean ± SD (n = 2, 
****P < 0.0001)
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3.3  In vitro binding stability of the antibodies conjugated 
to the NPs
The in vitro binding stability of the antibodies conjugated 
to the NPs was calculated by measuring the number of 
antibodies remaining conjugated to the nanoparticles 
after incubating the NPs in DPBS. The BCA assay was 
utilized to measure the remaining number of antibodies 
conjugated to the NPs and compared it with the initial 
number of conjugated antibodies (Fig.  2B). The f(ab′)2-
CD8a NPs demonstrated excellent stability under shaking 
conditions, with 99 % of its initial antibodies remaining 
until day 5. However, approximately 16 % of the con-
jugated antibodies of the full-CD8a NPs were reduced 
within five days, suggesting that the chemical bond-
ing stability of carbodiimide coupling in the full-CD8a 
NPs may be weaker than the maleimide coupling in the 
f(ab′)2-CD8a NPs. Thus, the stability of the f(ab′)2-CD8a 
NPs was superior to that of the full-CD8a NPs under 
prolonged periods of incubation. This confirms that the 
maleimide coupling procedure has a much longer shelf 
life than that of carbodiimide chemistry.
3.4  Immune cell targeting efficiency of the NPs in vitro
The immune cell-targeting efficiency of the antibody-
conjugated NPs was analyzed by treating the mouse 
splenocytes with 10  µg of DiD-loaded NPs for 10  min. 
The CD8 T and CD4 T cells were then analyzed for DiD 
signals through flow cytometry. The CD8 and CD4 T 
cells were primarily gate based on the expressions of the 
TCRβ, CD4, and CD8a markers on the surface of each 
cell (Additional file 1: Fig. S4A). The antibody-conjugated 
NPs interacted extensively with the CD8 T cells in com-
parison to the control NPs that were not conjugated with 
antibodies, suggesting that the antibody-conjugated NPs 
could successfully target the CD8 T cells.
The full-CD8a NPs-low and f(ab′)2-CD8a NPs-low vari-
ants and the full-CD8a NPs-medium and f(ab′)2-CD8a 
NPs-medium variants are pairs with similar numbers of 
surface antibodies. On the basis of the abovementioned 
statement (Fig.  3A), a direct comparison between the 
pairs’ binding efficiencies was conducted, which indi-
cated that the average increment in the DiD + CD8 T 
cell population induced by the f(ab′)2-CD8a NPs-low 
variant (66 %) was 1.61 times that of the full-CD8a NPs-
low variant (41 %). Similarly, the average increment in 
Fig. 3 T cell targeting efficiency of the CD8a‑conjugated NPs in vitro. A Binding of the anti‑CD8a conjugated NPs to the CD8a T cells. The mouse 
splenocytes were treated with the NPs for 10 min after loading the NPs with DiD and assessed through flow cytometry. B Observed DiD signal in 
the CD4 T cells that confirms the minimal non‑specific binding of the anti‑CD8a conjugated NPs, and (C) Comparison between the populations 
of the DiD‑expressing CD8 T cells induced by the full‑CD8a NPs and f(ab′)2‑CD8a NPs at different instants. Data were presented as the mean ± SD 
(n = 3, *P = 0.0332, **P = 0.0021, ***P = 0.0002, ****P < 0.0001)
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the DiD + CD8 T cell population induced by the f(ab′)2-
CD8a NPs-medium variant (80 %) was 1.2 times that of 
the full-CD8a NPs-medium variant (67 %). Further, the 
average increment in the DiD + CD8 T cell population 
induced by the f(ab′)2-CD8a NPs-high variant (90 %) 
was 1.3 times that of the full-CD8a NPs-high variant 
(67 %). This indicates that the f(ab′)2-CD8a NPs have a 
higher targeting efficiency than that of the full-CD8a 
NPs. The non-specific binding of the NPs was evaluated 
by analyzing the DiD signals obtained from the CD4 T 
cells because both NPs were not designed to target them 
(Fig. 3B). The minimal presence of the DiD + CD4 T cells 
in all NP groups was found to be similar to that of the 
control NPs. The non-specific binding nature of the NPs 
at different instants is shown in Additional file  1: Fig. 
S4B. These results suggest that the antibody-conjugated 
NPs can successfully target specific cells without unde-
sired non-specific bindings, irrespective of their conjuga-
tion chemistry. It provides an experimental insight into 
the possibility of utilizing of antibody-conjugated NPs as 
effective platforms of target delivery.
The mouse splenocytes were co-incubated with NPs 
for a period greater than 10 min (Fig. 3C). The prolonged 
incubation increased the population of the DiD + CD8 
T cells. The f(ab′)2-CD8a NPs-low, f(ab′)2-CD8a NPs-
medium, and f(ab′)2-CD8a NPs-high variants attained 
binding efficiencies of nearly 100 % after 90  min of co-
incubation. However, the binding efficiencies of the full-
CD8a NPs-low, full-CD8a NPs-medium, and full-CD8a 
NPs-high variants were limited to approximately 80 %. 
These results demonstrate that the binding efficiencies 
of the f(ab′)2-CD8a NPs are superior to those of the full-
CD8a NPs in vitro. The population of the DiD + CD8 
T cells increased at all instants for all variants after 
increasing the amount of DiD loaded NPs to 20 µg (Addi-
tional file 1: Fig. S4C). Thus, the in vitro data indicate that 
the f(ab′)2-CD8a NPs can bind to the CD8 T cells more 
quickly and efficiently than the full-CD8a NPs.
The difference between the binding efficiencies of 
the f(ab′)2-CD8a NPs and full-CD8a NPs can be attrib-
uted to the random orientation of the full-length anti-
bodies conjugated to the full-CD8a NPs. This study 
utilized the carbodiimide coupling method to conjugate 
full-length antibodies to the surfaces of the fc region. 
Previous studies have reported that the experimental 
condition frequently required during the implementa-
tion of the conventional carbodiimide coupling methods 
is also capable of inducing active conjugation through 
the antibody’s f(ab′)2 region, which possesses highly 
reactive amine moieties [16]. The full-length antibod-
ies conjugated to the full-CD8a NPs may not be oriented 
appropriately due to the presence of competing regions 
thereby, limiting their antigen-binding efficiency. How-
ever, this interpretation requires further imaging of the 
surfaces of the NP through an ultra-high resolution SEM 
for proper verification.
3.5  Immune cells targeting efficiency of the NPs in vivo
Based on the stability of conjugated antibodies and 
in vitro binding efficiency, the f(ab′)2-CD8a NPs-medium 
was selected for further in vivo CD8 T cell targeting effi-
ciency test. The f(ab′)2-CD8a NPs-medium was injected 
through the IV route. The mouse spleen and blood sam-
ples were taken at different instants (1, 3, and 6  h) and 
analyzed through flow cytometry (Scheme  2). The pop-
ulation of the DiD + CD8 T cells observed in the spleen 
Scheme 2 Analysis of the T cell targeting efficiency of the f(ab′)2‑CD8a NPs in vivo. The F(ab′)2‑CD8a NPs were administered to a mice model 
through an intravenous injection. The spleen and blood from the injected mouse were collected after 1–6 h and analyzed through flow cytometry 
to confirm the existence of the DiD + CD8 T cells
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was 88.6 and 98.59 % in the blood of the mice injected 
with f(ab′)2-CD8a medium NPs (Fig. 4A).
A rapid reduction in the population of the DiD + CD8 
T cells was observed after one hour of in  vivo circula-
tion, irrespective of the administered NPs (Fig. 4B). This 
reduction in the DiD signals suggests that the f(ab′)2-
CD8a-medium experienced active systematic clearance 
after 3 and 6  h of circulation in the spleen and blood, 
respectively.
4  Conclusions
We prepared and compared the targeting efficiencies of 
full-CD8a NPs and f(ab′)2-CD8a NPs in this study, both 
in vivo and in vitro. The SEM and DLS data showed that 
the variations between the sizes and morphologies of 
both NPs are minimal. The number and stability of the 
antibodies conjugated to the NP surfaces of the f(ab′)2-
CD8a NPs were higher than those of the NP surfaces of 
the full-CD8a NPs. The in  vitro data confirmed that the 
cell-binding ability of the f(ab′)2-CD8a NPs was more rapid 
and efficient than that of the full-CD8a NPs. And also, the 
f(ab′)2 -CD8a NPs showed successfully in  vivo targeting 
ability through the flow cytometry analysis of the spleen 
and blood in the mouse injected with the f(ab′)2-CD8a 
NPs. The results confirm that the f(ab′)2-CD8a NPs are 
highly capable of minimizing non-specific binding while 
exhibiting excellent cell-targeting efficiency, thereby con-
firming its enormous potential as a future target delivery 
platform in comparison to the full-CD8a NPs. Therefore, 
the proposed new type of antibody conjugation method 
combined with biocompatible polymeric NPs can be a 
promising candidate that might overcome the limitations 
Fig. 4 CD8a T cell targeting efficiency of the f(ab′)2‑CD8a NPs‑medium in vivo. A Population of the DiD + CD8 T cells after 1 h of circulation. The 
NPs are administered through IV injection and assessed through flow cytometry. B Clearance of the administered NPs observed by the variation 
of the population of the DiD + CD8 T cells across prolonged circulation. Data were presented as the mean ± standard error of the mean (n = 3, 
**P = 0.0021, ****P < 0.0001)
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of the current NP-based target delivery platform using 
complete antibodies.
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